October 15, 2008 – Neovasc Inc., a new specialty vascular device company comprised of the former Medical Ventures Corp., Neovasc Medical Ltd. and B-Balloon Ltd., featured its Metricath intravascular measurement device at TCT 2008.

Metricath is an arterial and in-stent measurement system that provides precise diameter and cross-sectional area measurements to aid in stent size selection and optimization.

For more information: www.neovasc.com

October 15, 2008 - Cardiogenesis Corp. sponsored an educational symposium entitled "New Horizons in Cardiac Regenerative Medicine: Advancements in Revascularization & Stem Cell Therapy," this week in conjunction with the TCT meeting in Washington, D.C.

October 15, 2008 - Advanced Circulatory Systems Inc. announced this week it has received an additional $1.5 million in funding from the National Institutes of Health (NIH) to continue a study testing two devices used in combination on those who experience cardiac arrest outside a hospital, where the national average for survival is only one in 20.

October 15, 2008 – TeraMedica reported that it won the Frost & Sullivan (F&S) 2008 Customer Value Enhancement Award in the North American Imaging Informatics Markets.

TeraMedica’s portfolio includes product solutions such as Evercore and Univision, which F&S said allow consolidating the multitude of patient data and digital healthcare information under one umbrella and servicing EMR, EHR and RHIO domains with technology such as a service-oriented architecture (SOA) and health information exchanges (HIE).

October 15, 2008 – The latest update to an independently conducted pooled data analysis shows that Medtronic’s Endeavor drug-eluting stent (DES) is distinguished by persistently strong safety benefits for patients with coronary artery disease.

Called ENDEAVOR-Safety, the analysis now includes more than 1,100 patients followed to four years.

October 15, 2008 – Two-year results from the ENDEAVOR-IV clinical trial show that the Endeavor drug-eluting stent (DES) from Medtronic Inc. is associated with statistically fewer heart attacks than Boston Scientific’s Taxus DES.

Martin B. Leon, M.D., founder and chairman emeritus of the Cardiovascular Research Foundation and principal investigator of ENDEAVOR-IV, presented the results at TCT 2008.

October 15, 2008 – At TCT 2008, Boston Scientific Corp. announced 12-month left main and three-vessel disease subset data from its landmark SYNTAX trial comparing percutaneous coronary intervention (PCI) using the TAXUS Express2 Paclitaxel-Eluting Coronary Stent System to contemporary coronary artery bypass graft (CABG) surgery.

October 15, 2008 - The new name and branding for MEDRAD’s interventional products division was unveiled to the public at TCT 2008 under the name MEDRAD Interventional/Possis.

October 15, 2008 - Boston Scientific Corp. announced estimated U.S. market shares for September for its two drug-eluting stents (DES), based on preliminary data from Millennium Research Group (MRG), a provider of strategic information to the healthcare sector.

Based on the MRG data, the company estimates its share percentages of the U.S. DES market for September as follows:

- Boston Scientific’s PROMUS Everolimus-Eluting Coronary Stent System: 25 percent

- Boston Scientific’s TAXUS Express2 Paclitaxel-Eluting Coronary Stent System: 19 percent

October 15, 2008 - At TCT 2008, Philips Healthcare is showcasing cath lab improvements, designed to present users with seamless interaction between image acquisition and visualization technologies, hemodynamic monitoring and charting, cath lab and statistical reporting, and multimodality image access, viewing and storage.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now